Zinnat, 125 mg 10 pcs

Zinnate is a II generation oral cephalosporin antibiotic. It acts bactericidally, disrupts synthesis of the bacterial cell wall. It has a broad spectrum of action.

It is resistant to most beta-lactamases.

Zinnate is highly active against aerobic gram-positive bacteria: Staphylococcus aureus, Staphylococcus epidermidis (including penicillin-resistant strains and except for rare methicillin-resistant strains), Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus group B (Streptococcus agalactiae), Streptococcus mitis (viridans group), Bordetella pertusis; aerobic gram-negative bacteria: Escherichia coli, Klebsiella spp., Proteus mirabilis, Providencia spp, Proteus rettgeri, Haemophilus influenzae (including ampicillin-resistant strains), Haemophilus parainfluenzae (including ampicillin-resistant strains), Moraxella (Branhamella) catarrhalis, Neisseria gonorrhoeae (including penicillinase-producing and non-producing strains), Neisseria meningitidis, Salmonella spp.Anaerobic gram-positive bacteria: Peptococcus spp, Peptostreptococcus spp, Clostridium spp, Propionibacterium spp; anaerobic gram-negative bacteria: Bacteroides spp, Fusobacterium spp; also active against Borrelia burgdorferi.

Cefuroxime is resistant to Clostridium difficile, Pseudomonas spp., Campylobacter spp., Acinetobacter calcoaceticus, Listeria monocytogenes, methicillin-resistant strains of Staphylococcus aureus, methicillin-resistant strains of Staphylococcus epidermidis, Legionella spp.

In in vitro studies it has been shown that when combining cefuroxime with antibiotics from the group of aminoglycosides an additive effect is observed and in some cases synergism.

Indications

Treatment of infectious and inflammatory diseases caused by microorganisms sensitive to the drug:

respiratory tract infections (including acute and chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess, postoperative chest infections);
infections of the ear, throat, nose (including sinusitis, tonsillitis, pharyngitis, acute otitis media);
infections of the genitourinary system (including acute and chronic pyelonephritis, cystitis, urethritis, asymptomatic bacteriuria);
infections of the skin and soft tissues (including furunculosis, pyoderma, impetigo);
gonorrhea (including acute uncomplicated gonococcal urethritis and cervicitis);
treatment of Lyme disease at an early stage and subsequent prevention of late manifestations in adults and children over 12 years of age.

Pharmacological effect

Zinnat is a second generation cephalosporin antibiotic for oral administration. It has a bactericidal effect and disrupts the synthesis of bacterial cell walls. Has a wide spectrum of action.

Resistant to most beta-lactamases.

Zinnat is highly active against aerobic gram-positive bacteria: Staphylococcus aureus, Staphylococcus epidermidis (including strains resistant to penicillins and with the exception of rare methicillin-resistant strains), Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus group B (Streptococcus agalactiae), Streptococcus mitis (group viridans), Bordetella pertusis; aerobic gram-negative bacteria: Escherichia coli, Klebsiella spp., Proteus mirabilis, Providencia spp., Proteus rettgeri, Haemophilus influenzae (including ampicillin-resistant strains), Haemophilus parainfluenzae (including ampicillin-resistant strains), Moraxella (Branhamella) catarrhalis, Neisseria gonorrhoeae (including strains producing and not producing penicillinase), Neisseria meningitidis, Salmonella spp.; anaerobic gram-positive bacteria: Peptococcus spp., Peptostreptococcus spp., Clostridium spp., Propionibacterium spp.; anaerobic gram-negative bacteria: Bacteroides spp, Fusobacterium spp.; also active against Borrelia burgdorferi.

Clostridium difficile, Pseudomonas spp., Campylobacter spp., Acinetobacter calcoaceticus, Listeria monocytogenes, methicillin-resistant strains of Staphylococcus aureus, methicillin-resistant strains of Staphylococcus epidermidis, Legionella spp. are resistant to cefuroxime.

In vitro studies have shown that when cefuroxime is combined with aminoglycoside antibiotics, an additive effect is observed, and in some cases, synergism.

Special instructions

With long-term use of Zinnat, increased growth of resistant microorganisms (Candida, Enterococci, Clostridium difficile) is possible, which may require discontinuation of treatment.

When diarrhea occurs due to the use of antibiotics, incl. Zinnat, one should keep in mind the possibility of developing pseudomembranous colitis.

When treating Lyme disease with Zinnat, a Jarisch-Gersheimer reaction is sometimes observed.

This reaction is a direct consequence of the bactericidal effect of Zinnat on the causative agent of the disease – the spirochete Borrelia burgdorferi.

Patients should be advised that this is a common and normal consequence of antibiotic treatment for Lyme disease.

Active ingredient

Cefuroxime

Composition

1 tablet contains cefuroxime 250 mg;

excipients:

MCC,

croscarmellose sodium,

sodium lauryl sulfate,

hydrogenated vegetable oil,

colloidal silicon dioxide,

methylhydroxypropylcellulose,

propylene glycol,

methyl parahydroxybenzoate,

propyl parahydroxybenzoate,

opaspray white.

Contraindications

Hypersensitivity to cephalosporin antibiotics.

Use with caution in the first trimester of pregnancy and lactation.

Side Effects

From the digestive system: nausea, vomiting, diarrhea; possible temporary increase in the activity of liver enzymes (ALT, AST, LDH), jaundice; Cases of pseudomembranous colitis have been described.

From the hematopoietic system: hemolytic anemia, eosinophilia, neutropenia, thrombocytopenia, leukopenia (sometimes pronounced).
Allergic reactions: skin rash, itching, urticaria, fever, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, serum sickness; in isolated cases – anaphylaxis.

From the side of the central nervous system: headache.

Other: positive Coombs reaction.

Interaction

Co-administration of cefuroxime and probenecid results in an increase in the AUC of cefuroxime by 50%.

Storage conditions

At a temperature not exceeding 30 °C

Shelf life

3 years

Manufacturer

Glaxo Operations UK Ltd, UK